Claims for Patent: 9,585,955

Summary for Patent: 9,585,955

Title:	Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
Abstract:	The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5.omega.3], decosahexaenoic acid [C22: 6.omega.3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
Inventor(s):	Grobler; Anne Frederica (Potchefstroom, ZA), Kotze; Abraham Frederik (Potchefstroom, ZA)
Assignee:	North-West University (Potchefstroom, ZA)
Application Number:	14/075,681
Patent Claims:	1. A method of enhancing direct or subsequent immunological responses to a vaccine containing an antigen, comprising the step of administering a composition of the vaccine combined with an adjuvant, wherein the antigen of the vaccine is not inactivated by nitrous oxide and, wherein the adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent selected from the group consisting of water, one or more of a pharmaceutically acceptable alcohol, ether, oil or polymer including polyethylene glycol and which adjuvant further comprises at least one fatty acid or a suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkylesters thereof, the glycerol-polyethylene glycol esters thereof and a reaction product of hydrogenated natural oils comprising ricinoleic acid based oils. 2. A pharmaceutical preparation comprising a composition of an adjuvant combined with a vaccine containing an antigen, wherein the antigen is not inactivated by nitrous oxide and, wherein the adjuvant comprises a solution of nitrous oxide in a pharmaceutically acceptable carrier solvent selected from the group consisting of water and one or more of a pharmaceutically acceptable alcohol, ether, oil or polymer including polyethylene glycol and which adjuvant further comprises at least one fatty acid or a derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and derivatives thereof selected from the group consisting of C1 to C6 alkyl esters thereof, glycerol-polyethylene glycol esters thereof and reaction products of hydrogenated natural oils comprising ricinoleic acid based oils. 3. The method of claim 1 in which the antigen of the vaccine utilized in the method is selected from the group consisting of antigenic peptides, inactivated viruses, inactivated bacteria and virus-like particles (VLPs). 4. The method of claim 1 wherein the antigen of the vaccine is suitable to elicit an immunogenic response against the causative agent of an ailment, or infection by an agent, selected from the group consisting of: Bacillus Calmette-Guerin Cholera, Haemophilus Type B, Meningococcal, Pertussis, Pneumococcal, Tetanus, Typhoid, Diphtheria, Hepatitis A, Hepatitis B, Humanpapilloma virus, Influenza, Measles, Mumps, Poliomyelitis, Rabies, Rubella, Tick-borne Encephalitis, Varicella and Yellow Fever. 5. The method of claim 1 wherein the reaction product of hydrogenated natural oils comprising ricinoleic acid based oils with ethylene oxide is produced from castor oil of which the fatty acid content is known to be predominantly composed of ricinoleic acid. 6. The method of claim 1 wherein the solution is an aqueous solution saturated with nitrous oxide, the water being deionised and purified to be free of microbes and endotoxins. 7. The method of claim 1 wherein the composition is in a liquid presentation for oral administration or in a nasal or bronchial or pulmonary spray formulation or in the form of an injectable formulation, and wherein the composition incorporates the solvent, into which the nitrous oxide is dissolved and in which the fatty acid(s) or ester(s) thereof is either dissolved or suspended or emulsified along with the antigen by being formulated therewith. 8. The method of claim 1 wherein the composition is for administration to the patient as a topical, buccal, nasal or vaginal cream, ointment, spray, lotion or as a suppository, and the composition incorporates the solvent containing, and preferably saturated with, nitrous oxide and, the long chain fatty acid(s) or ester(s) thereof, and, additional optional excipients and carriers. 9. The preparation of claim 2 wherein the composition is made up to be suited to transdermal application as an injectable, ointment, cream or lotion or is in the form of a skin patch providing a reservoir for the composition. 10. The method of claim 1 wherein the fatty acid component of the composition is constituted by the complex known as Vitamin F Ethyl Ester. 11. The method of claim 1 wherein the composition is prepared to be adapted for mucosal administration and in particular nasal administration. 12. A preparation as claimed in claim 2 wherein the composition includes one or more vaccines that render the composition suitable for use to vaccinate against an infectious agent, the vaccine being selected from the group consisting of Bacillus Calmette-Guerin Vaccine, Cholera Vaccine, Haemophilus Type B Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Pertussis Vaccine, Pneumococcal Polysaccharide Vaccine, Tetanus Vaccine, Typhoid Vaccine, Diphtheria Vaccine, Tetanus Vaccine, Inactivated Hepatitis A Vaccine, Hepatitis B Vaccine (peptide), Inactivated Influenza Vaccine (Whole Virion), Inactivated Influenza Vaccine (Split Virion), Inactivated Influenza Vaccine (Surface Antigen), Measles Vaccine, Live_Mumps Vaccine, Poliomyelitis Vaccine, Live (Oral)_Rabies Vaccine, Rubella Vaccine, Live_Tick-borne Encephalitis Vaccine, Inactivated Varicella Vaccine, Live Yellow Fever Vaccine, Diphtheria and Tetanus Vaccine, Diphtheria, Tetanus and Pertussis Vaccine, Diphtheria, Tetanus and Pertussis (Acellular Component)_Vaccine, Diphtheria, Tetanus and Pertussis (Acellular Component)_and Haemophilus Type B Conjugate Vaccine, Diphtheria, Tetanus and Pertussis (Acellular Component)_and Hepatitis B (peptide) Vaccine, Diphtheria, Tetanus and Pertussis (Acellular Component)_and Inactivated Poliomyelitis Vaccine, Hepatitis A (Inactivated) and Hepatitis B (rDNA) Vaccine, and Measles, Mumps and Rubella Vaccine, Live. 13. The preparation of claim 2 in which the vaccine or vaccines_utilized in the formulation is or are selected from the group consisting of antigenic peptides, inactivated viruses, inactivated bacteria and virus-like particles (VLPs). 14. The preparation of claim 2 wherein the vaccine is suitable to elicit an immunogenic response against the causative agent of an ailment, or infection by an agent, selected from the group consisting of Tuberculosis, Cholera, Haemophilus Type B, Meningococcal, Pertussis, Pneumococcal, Tetanus, Typhoid, Diphtheria, Hepatitis A, Hepatitis B, Human.sub.-- apilloma virus, Influenza, Measles, Mumps, Poliomyelitis, Rabies, Rubella, Tick-borne Encephalitis, Varicella and Yellow Fever. 15. The preparation of claim 2 wherein the reaction product of hydrogenated natural oils comprising ricinoleic acid based oils with ethylene oxide is produced from castor oil of which the fatty acid content is predominantly composed of ricinoleic acid. 16. The preparation of claim 2 wherein the solution is an aqueous solution saturated with nitrous oxide, the water being deionized and purified to be free of microbes and endotoxins. 17. The preparation of claim 2 which is in a liquid formulation for oral administration or in a nasal or bronchial or pulmonary spray formulation or in an injectable formulation, and wherein the composition incorporates the solvent into which the nitrous oxide is dissolved and the fatty acid(s) or ester(s) thereof which is either dissolved or suspended or emulsified. 18. The preparation of claim 2 formulated to be administered to the patient by topical, buccal, nasal or vaginal cream, ointment, spray, lotion or as a suppository, and wherein such preparation incorporates the solvent containing, and preferably saturated with, nitrous oxide, the long chain fatty acid(s) or ester(s) thereof and additional optional excipients and carriers. 19. The preparation of claim 2 wherein the reaction product is castor oil with ethylene oxide. 20. The method of claim 1 wherein the reaction product is castor oil with ethylene oxide. 21. The preparation of claim 2 wherein the fatty acid component of the composition is constituted by the complex known as Vitamin F Ethyl Ester. 22. The preparation of claim 2 adapted for mucosal administration and in particular nasal administration.

Details for Patent 9,585,955

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	June 21, 1989	9,585,955	2033-11-08
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	October 20, 1997	9,585,955	2033-11-08
Glaxosmithkline Biologicals	HAVRIX	hepatitis a vaccine	Injection	103475	February 22, 1995	9,585,955	2033-11-08